MACRO Trial
Cross-source consensus on MACRO Trial from 1 sources and 5 claims.
1 sources · 5 claims
Benefits
Comparisons
Evidence quality
Other
Highlighted claims
- The MACRO trial compared endoscopic sinus surgery, clarithromycin, and placebo in patients with chronic rhinosinusitis with and without nasal polyps. — Chronic rhinosinusitis: a qualitative study of patient and clinician experiences of the MACRO randomised controlled trial of surgical versus medical management
- MACRO was conducted across 21 secondary and tertiary ENT centres in England and Scotland between 2018 and 2023. — Chronic rhinosinusitis: a qualitative study of patient and clinician experiences of the MACRO randomised controlled trial of surgical versus medical management
- The trial randomised 514 chronic rhinosinusitis patients and followed them for 6 months. — Chronic rhinosinusitis: a qualitative study of patient and clinician experiences of the MACRO randomised controlled trial of surgical versus medical management
- The main MACRO trial found ESS significantly better than clarithromycin or placebo at 6 months on patient-reported SNOT-22 scores. — Chronic rhinosinusitis: a qualitative study of patient and clinician experiences of the MACRO randomised controlled trial of surgical versus medical management
- Clarithromycin did not show significant benefit over placebo in the MACRO trial. — Chronic rhinosinusitis: a qualitative study of patient and clinician experiences of the MACRO randomised controlled trial of surgical versus medical management